Company: PTHS
Filing Date: 2025-05-27
Form Type: DEFM14C
Source: 0001140361-25-020509
Chunk: 301

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-05-27
Form: DEFM14C
Chunk 301
---
 competitive. Several pharmaceutical companies that are developing molecules that modulate NaV (including NaV1.7 and NaV1.8) activities or address pain through other methods of action and therefore have the potential to mitigate eye, post-surgical and EM and iSFN pain. These companies and new entrants may potentially compete with Channel’s products in the future with novel delivery technologies. Competition in this space will remain strong and Channel does not know if it will be successful in obtaining orphan designation from the FDA for CC8464, encounter challenges to its issued patents and continue to advance CC8464, C2000 and CT3000 through clinical development towards approval.

In connection with Channel’s IPO, Channel entered into a side letter with Chromocell Holdings, pursuant to which Chromocell Holdings agreed not to (i) directly or indirectly engage in the business of owning, licensing, developing, marketing, manufacturing, producing, selling or distributing products, technologies, therapies, or services in any way related to Channel’s business, including all patents, pre-clinical and Phase I study results and data, and trade secrets related to the CC8464 compound, transferred by Chromocell Holdings to Channel further to the that certain Contribution Agreement (the “Contribution Agreement”) with Chromocell Holdings. Pursuant to the Contribution Agreement, effective July 12, 2022, (ii) directly or indirectly, hire, engage or employ (as an employee, consultant or otherwise) any of Channel’s employees; provided that Chromocell Holdings shall not, directly or indirectly, prevent any of Channel’s employees from serving on the board of directors of Chromocell Holdings, and (iii) through any director or officer of Chromocell Holdings, directly or indirectly, solicit for employment or the engagement of services of any of Channel’s employees or induce or attempt to induce any of Channel’s employees to leave his or her employment with Channel, or in any way intentionally interfere with the employment relationship between any of Channel’s employees and Channel, for the purpose of employing or engaging the services of such employee or soliciting such employee to become an employee or consultant of Chromocell Holdings or any other person.

#### Channel’s Facilities
Channel’s office is located at 4400 Route 9 South, Suite 1000, Freehold, NJ 07728.

<div align='center'>168</div>

#### TABLE OF CONTENTS

#### Employees and Human Capital Resources
As of May 23, 2025, Channel had four full-time employees and